Cargando…
Translational drug–interaction corpus
The discovery of drug–drug interactions (DDIs) that have a translational impact among in vitro pharmacokinetics (PK), in vivo PK and clinical outcomes depends largely on the quality of the annotated corpus available for text mining. We have developed a new DDI corpus based on an annotation scheme th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216474/ https://www.ncbi.nlm.nih.gov/pubmed/35616099 http://dx.doi.org/10.1093/database/baac031 |
_version_ | 1784731430044041216 |
---|---|
author | Zhang, Shijun Wu, Hengyi Wang, Lei Zhang, Gongbo Rocha, Luis M Shatkay, Hagit Li, Lang |
author_facet | Zhang, Shijun Wu, Hengyi Wang, Lei Zhang, Gongbo Rocha, Luis M Shatkay, Hagit Li, Lang |
author_sort | Zhang, Shijun |
collection | PubMed |
description | The discovery of drug–drug interactions (DDIs) that have a translational impact among in vitro pharmacokinetics (PK), in vivo PK and clinical outcomes depends largely on the quality of the annotated corpus available for text mining. We have developed a new DDI corpus based on an annotation scheme that builds upon and extends previous ones, where an abstract is fragmented and each fragment is then annotated along eight dimensions, namely, focus, polarity, certainty, evidence, directionality, study type, interaction type and mechanism. The guideline for defining these dimensions has undergone refinement during the annotation process. Our DDI corpus comprises 900 positive DDI abstracts and 750 that are not directly relevant to DDI. The abstracts in corpus are separated into eight categories of DDI or non-DDI evidence: DDI with pharmacokinetic (PK) mechanism, in vivo DDI PK, DDI clinical, drug–nutrition interaction, single drug, not drug related, in vitro pharmacodynamic (PD) and case report. Seven annotators, three annotators with drug–interaction research experience and four annotators with less drug–interaction research experience independently annotated the DDI corpus, where two researchers independently annotated each abstract. After two rounds of annotations with additional training in between, agreement improved from (0.79, 0.96, 0.86, 0.70, 0.91, 0.65, 0.78, 0.90) to (0.93, 0.99, 0.96, 0.94, 0.95, 0.93, 0.96, 0.97) for focus, certainty, evidence, study type, interaction type, mechanisms, polarity and direction, respectively. The novice-level annotators improved from 0.83 to 0.96, while the expert-level annotators stayed in high performance with some improvement, from 0.90 to 0.96. In summary, we achieved 96% agreement among each pair of annotators with regard to the eight dimensions. The annotated corpus is now available to the community for inclusion in their text-mining pipelines. Database URL https://github.com/zha204/DDI-Corpus-Database/tree/master/DDI%20corpus |
format | Online Article Text |
id | pubmed-9216474 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92164742022-06-23 Translational drug–interaction corpus Zhang, Shijun Wu, Hengyi Wang, Lei Zhang, Gongbo Rocha, Luis M Shatkay, Hagit Li, Lang Database (Oxford) Original Article The discovery of drug–drug interactions (DDIs) that have a translational impact among in vitro pharmacokinetics (PK), in vivo PK and clinical outcomes depends largely on the quality of the annotated corpus available for text mining. We have developed a new DDI corpus based on an annotation scheme that builds upon and extends previous ones, where an abstract is fragmented and each fragment is then annotated along eight dimensions, namely, focus, polarity, certainty, evidence, directionality, study type, interaction type and mechanism. The guideline for defining these dimensions has undergone refinement during the annotation process. Our DDI corpus comprises 900 positive DDI abstracts and 750 that are not directly relevant to DDI. The abstracts in corpus are separated into eight categories of DDI or non-DDI evidence: DDI with pharmacokinetic (PK) mechanism, in vivo DDI PK, DDI clinical, drug–nutrition interaction, single drug, not drug related, in vitro pharmacodynamic (PD) and case report. Seven annotators, three annotators with drug–interaction research experience and four annotators with less drug–interaction research experience independently annotated the DDI corpus, where two researchers independently annotated each abstract. After two rounds of annotations with additional training in between, agreement improved from (0.79, 0.96, 0.86, 0.70, 0.91, 0.65, 0.78, 0.90) to (0.93, 0.99, 0.96, 0.94, 0.95, 0.93, 0.96, 0.97) for focus, certainty, evidence, study type, interaction type, mechanisms, polarity and direction, respectively. The novice-level annotators improved from 0.83 to 0.96, while the expert-level annotators stayed in high performance with some improvement, from 0.90 to 0.96. In summary, we achieved 96% agreement among each pair of annotators with regard to the eight dimensions. The annotated corpus is now available to the community for inclusion in their text-mining pipelines. Database URL https://github.com/zha204/DDI-Corpus-Database/tree/master/DDI%20corpus Oxford University Press 2022-05-25 /pmc/articles/PMC9216474/ /pubmed/35616099 http://dx.doi.org/10.1093/database/baac031 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Zhang, Shijun Wu, Hengyi Wang, Lei Zhang, Gongbo Rocha, Luis M Shatkay, Hagit Li, Lang Translational drug–interaction corpus |
title | Translational drug–interaction corpus |
title_full | Translational drug–interaction corpus |
title_fullStr | Translational drug–interaction corpus |
title_full_unstemmed | Translational drug–interaction corpus |
title_short | Translational drug–interaction corpus |
title_sort | translational drug–interaction corpus |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216474/ https://www.ncbi.nlm.nih.gov/pubmed/35616099 http://dx.doi.org/10.1093/database/baac031 |
work_keys_str_mv | AT zhangshijun translationaldruginteractioncorpus AT wuhengyi translationaldruginteractioncorpus AT wanglei translationaldruginteractioncorpus AT zhanggongbo translationaldruginteractioncorpus AT rochaluism translationaldruginteractioncorpus AT shatkayhagit translationaldruginteractioncorpus AT lilang translationaldruginteractioncorpus |